Amsterdam, the Netherlands, 4 November 2022 – Freya Pharma Solutions, a late clinical stage
pharmaceutical company focusing on the development of effective pharmaceutical therapies for
women diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD), has presented the design of
its upcoming ALETTA pivotal clinical trial with LybridoTM at the 23rd ISSM/SMSNA Scientific Meeting.
The International Society for Sexual Medicine (ISSM) Scientific Meeting & 23rd Annual Fall Scientific
Meeting of Sexual Medicine Society of North America (SMSNA), was held late October 2022 in Miami
Beach, Florida. The paper titled “Design of the ALETTA Clinical Study: A Randomized Double-Blind
Placebo-Controlled Study investigating the Efficacy and Safety of LybridoTM in Premenopausal Women
with Acquired FSIAD”, was presented by first author Dr. Cobi Reisman and got a warm scientific
reception by attending health professionals from all over the world.

Dr. Jan van der Mooren, Chief Medical Officer of Freya, stated:

“Presenting our ALETTA trial at this conference is an important step in acquiring feedback from an
audience of international professionals in sexual medicine on our clinical development plans. The
abundance of positive comments confirms our belief that there is a great unmet need for an
effective treatment of female sexual problems, and that LybridoTM has the potential to fill in that
gap. The concept of LybridoTM, creating a unique synergy of testosterone and sildenafil, is
recognized by international experts as an innovative drug on a market with only two approved
drugs for FSIAD in the United States, while no drug being approved in Europe so far.”

Freya Pharma Solutions is currently preparing the clinical development program with several studies
in Europe, to be followed later by additional trials in the United States. The company is highly confident
that it is well on track with the clinical development of LybridoTM as a treatment for women suffering
from sexual dysfunction, and the related distress which often negatively interferes with their quality
of life and their relationships.



Low sexual desire is consistently reported as the most common sexual complaint in women. As a result, many women are dissatisfied with their sex lives, which often affects their social and emotional wellbeing. FSIAD is a sexual dysfunction that is defined in the 2013 version of the DSM-5 Diagnostic and Statistical Manual of Mental Disorders, a publication by the American Psychiatric Association, as a persistent lack or significant reduction of sexual interest and/or arousal. Persons can be medically diagnosed after having a well-defined number of symptoms causing clinically significant distress and which have persisted for a minimum of six months. The disorder is specified by severity level and subtyped into lifelong versus acquired, generalized versus situational.

About Lybrido

A total of 20 phase 1 and phase 2a trials and large-scale phase 2b trials in 17 research sites in the US have been conducted to date. These trials have investigated the efficacy and safety of two novel on-demand pharmacological treatments that have been designed to treat two FSIAD subgroups: women with low sensitivity for sexual cues (Lybrido) and women with over-activation of sexual inhibition (Lybridos). Lybrido increases central sexual motivation and physiological sexual responses, such as swelling of vaginal erectile tissue and lubrication. The therapy can be taken ‘on demand’ and helps to increase central sexual motivation from three to six hours after intake. This treatment consists of a novel (dual-route, dual-release, fixed-dose) combination tablet consisting of a testosterone coating for sublingual administration and an inner-core component containing the phosphodiesterase type 5 (PDE 5) inhibitor, sildenafil. The inner-core component is coated with a delayed-release matrix to ensure that the peak plasma concentration of the sildenafil coincides with the window of increased sexual motivation induced by the testosterone component. Thus, this combination enables an increase in genital arousal through an increase in responsivity to sexual stimuli.

About Freya Pharma Solutions

Freya Pharma Solutions is a late clinical stage company focused on developing effective pharmaceutical therapies for FSIAD, building upon fifteen years of solid research. The company has two compounds in development, Lybrido and Lybridos, to address the range of potential causes of FSIAD. Based in Amsterdam, The Netherlands, Freya aims to offer patients a convenient, personalized ‘on demand’ solution for this recognized unmet medical need.


Please contact for further information:

Freya Pharma Solutions, Amsterdam

Marcel Wijma, Chief Executive Officer



For media

LifeSpring Life Sciences Communication, Amsterdam

Leon Melens

T: +31 6 538 16 427